The study adds to growing evidence that digital tools can maximize genetic counselors' limited time without patient harm.

Trump administration health officials assured drugmakers and researchers at a roundtable hosted by the FDA that they want to ...

Sarepta is the first company to publicly disclose that it's received the designation, for which the FDA had issued a draft guidance last year.

Vepdegestrant showed a benefit for patients with ER-positive, HER2-negative, ESR1-mutated breast cancer who had previously received endocrine-based therapy.

As with the drug's 2023 approval in castration-resistant tumors, it's not clear if it works comparably in all homologous ...